IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. GOOGL
6. USO
7. APGE
8. ABBV
9. DFTX
10. MSFT

Go back to IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
(NASDAQ: IDYA) Delayed: 34.23 --0 (-0%)
Previous Close $34.23    52 Week High $ 
Open $34.23    52 Week Low $ 
Day High $34.23    P/E N/A 
Day Low $34.23    EPS $ 
Volume 234